Transcutaneous Spinal Cord Stimulation in Children with Incomplete Spinal Cord Injury

Last updated: February 11, 2025
Sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Spinal Cord Injuries

Treatment

Gait training with/without TSCS

Clinical Study ID

NCT06242873
IRB00300695
  • Ages 3-16
  • All Genders

Study Summary

Aim 1: Determine the safety and feasibility of administration of TSCS to children in a clinical setting. Participants will be randomly assigned to experimental (TSCS) or control (sham stimulation) groups. Both groups will receive eight-weeks of individualized gait training. We will measure adverse events, including pain and skin irritation, to determine safety as the primary outcome. Hypothesis 1: Administration of TSCS to children in a clinical setting will be safe based on similar safety outcomes as sham TSCS. Hypothesis 2: TSCS is feasible based on compliance to session interventions and long-term adherence to the protocol. Additionally, we will collect data on effort during sessions of both participant and therapist. We anticipate that the participants will report less effort in the experimental condition, as compared to the control and therapists will report equal effort across conditions.

Aim 2: Determine the neurophysiologic impact of TSCS within a single session. We hypothesize that participants will demonstrate increased volitional muscle activity and strength with TSCS as compared to sham stimulation. This will be assessed by surface EMG and hand-held dynamometry of the dominant-side quadriceps muscle during maximum volitional contraction (MVC), across multiple time points. Changes in EMG activity will indicate change in central excitability in response to stimulation.

Aim 3: Exploratory measurement of TSCS and gait training on walking function. We hypothesize that concurrent TSCS and gait training will augment walking function in children with iSCI, as compared to gait training with sham stimulation. In addition to outcomes defined above, participants will be assessed with clinically relevant outcome measures, to include the Timed Up and Go, 10-Meter Walk Test, Walking Index for Spinal Cord Injury II, and 6-Minute Walk Test. Data collected as part of this aim will elucidate trends in responder qualities and timeline of changes to inform future studies.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 3-16

  • ≥ 6 months post injury

  • Non-progressive SCI

  • American Spinal Injury Association Impairment Scale (AIS) Classification C or D AISC is an incomplete classification where more than half of the key muscles below theneurological level have a muscle grade of 3 or less AIS D is an incompleteclassification where more than half of the key muscles below the neurological levelhave a muscle grade of more than 3

  • Neurologic level above T10

  • Tolerates upright position for >30 minutes

  • Able to advance one lower extremity (LE) when in standing, bracing and assistivedevice allowed

  • Medically stable (no hospitalizations in last 3 mos.)

  • Able to comply with The International Standards for neurological and functionalClassification of Spinal Cord Injury (ISNCSCI) exam

Exclusion

Exclusion Criteria:

  • Progressive Spinal Cord Injury or Disease (SCI/D) (Multiple Sclerosis, AcuteDisseminated Encephalomyelitis, etc.)

  • Active wounds

  • Range of motion limits impacting gait training

  • Cardiac pacemaker/defibrillator

  • Active cancer diagnosis

  • Absent LE reflexes

  • Pregnancy

Study Design

Total Participants: 20
Treatment Group(s): 1
Primary Treatment: Gait training with/without TSCS
Phase:
Study Start date:
March 03, 2022
Estimated Completion Date:
December 30, 2025

Connect with a study center

  • Kennedy Krieger Institute

    Baltimore, Maryland 21205
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.